⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 19, 2024Future OncologyOpen Access

Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs

Jiling Niu Xuquan Jing Qinhao Xu Haoyu Liu Yaru Tian Zhengqiang Yang Hui Zhu Yulan Sun

View Full Paper

Ask AI

Bookmark

Share

Abstract

Background: In first/second generation EGFR-TKIs, strong PD-L1 expression contributes to primary resistance, significantly affecting patient prognosis. The relationship between PD-L1 expression levels and third-generation TKIs remains unclear.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Niu et al. (2024) studied this question.

synapsesocial.com/papers/68e5bb33b6db643587553ace https://doi.org/10.1080/14796694.2024.2385290

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effect of strong programmed cell death ligand-1 (PD-L1) expressions on clinical outcomes in advanced non-small cell lung cancer treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitors.2024
2Strong programmed cell death ligand-1 affect clinical outcomes in advanced non-small cell lung cancer treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitors2024
3PD‐L1 expression is associated with inferior outcomes independent of <i>EGFR</i> subtype in advanced non–small cell lung cancer with uncommon <i>EGFR</i> mutations treated with first‐line second‐generation EGFR‐tyrosine kinase inhibitorsPrognostic Study · 2026 · 1 citations
4Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents2024 · 3 citations
5Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 ExpressionRetrospective Study · 2026 · 1 citations